Private AI for Australian Pharma

The deployment is built to satisfy CSV expectations under PIC/S Annex 11, with installation, operational and performance qualification documentation produced as part of the deployment. ALCOA+ record integrity applies to every model interaction. Change control covers the model, prompts and retrieval index. When a TGA GMP inspector asks how a particular regulatory document or PV narrative was prepared, you can produce the user, the prompt, the retrieved sources, the model version, and the full audit trail. We provide template SOPs that you can fold into your existing QMS for the human-in-the-loop steps. For partners — particularly originator pharma running audit programmes on their generics or distribution partners — the same evidence pack satisfies their typical audit requirements.

Yes, in a regulated drafting role with mandatory QPPV oversight. The model never finalises or transmits an ICSR autonomously. The pattern is: PV intake (a call-centre call, an HCP letter, an MA enquiry containing a potential AE) is processed by the model under your case-handling SOP, producing a draft narrative and proposed MedDRA coding in your case-management system; the QPPV or delegated PV scientist reviews, edits and approves the case in the system of record; the system of record is what gets transmitted to the TGA via DAEN. The role of the AI is to compress the intake-to-draft time so your PV team’s capacity is concentrated on review and signal detection, not on initial transcription. Every step is logged.

Multi-layered controls. At the prompt level, the medical-information workflow is grounded only in your approved Product Information, CMI and response repository — the model is structurally prevented from retrieving content from outside that perimeter unless an off-label enquiry is explicitly recognised. Recognised off-label enquiries trigger automatic escalation to a medical reviewer with the original enquiry text and a note about why the model declined to respond directly. At the model level, system prompts encode the Medicines Australia Code of Conduct (Edition 19) constraints. At the workflow level, every draft response goes through a human medical reviewer before release. Reviewer attribution is logged. The combination is materially safer than a free-text generic AI tool used in the same role.

Integration with Veeva Vault QualityDocs, RIM and PromoMats is supported through Vault’s standard API. For PV systems, the model integrates with ArisGlobal LifeSphere and Oracle Argus through their respective case-management APIs — the model writes drafts into the case management system, not into a parallel store. For QMS platforms (MasterControl, TrackWise, Veeva QMS) the model reads controlled documents in their current effective state through the platform API. The integration team configures connections during deployment, typically over two to three weeks. Where a system is on-premises and unable to expose an API, a controlled export-import pattern is used instead.

ChatGPT Enterprise provides a stronger contractual posture than the consumer version but does not satisfy the pharma-specific controls. It cannot demonstrate CSV evidence of its underlying model. It does not provide an audit trail at the granularity a TGA inspector would expect. Its retention model is improving but is not zero. Most importantly, it is a multi-tenant offering hosted on US infrastructure under US legal jurisdiction — for PV data containing identifiable patient information, that is a real exposure under Privacy Act 1988 cross-border transfer requirements. A custom LLM is single-tenant, runs on Australian sovereign infrastructure, is validated to your QMS, and the trained model is yours. We cover the comparison in detail at /chatgpt-enterprise-alternative-australia.

A mid-size sponsor (50–200 staff, multiple registered products) typically goes from kick-off to functional pilot in twelve to sixteen weeks: three weeks of GxP scoping and validation planning, six to eight weeks of validated ingestion and fine-tuning across PI/CMI, controlled SOPs, prior PBS submissions, ARTG records and PV history, then a four-week functional pilot inside one team (most often MI/PV or PBS submission support). Full rollout across regulatory affairs, medical affairs, PV and commercial follows over the subsequent three to six months as additional use cases pass change control. For a large multinational with global QMS expectations, the timeline is longer because the validation evidence pack is larger.

It works particularly well for generics and biosimilar manufacturers because the document-intensive parts of the work — tender preparation, PBS price disclosure analysis, originator competitive intelligence, ARTG entry maintenance and label harmonisation — are exactly where a private LLM delivers the most leverage. For biosimilar manufacturers specifically, the model can support the substitutability flagging analysis, the patient-and-prescriber acceptance correspondence and the originator-versus-biosimilar comparative literature work. The GxP, validation and Australian sovereign-hosting architecture is identical to originator deployments.